O. Tomé

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy—a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group

Felix Hilpert, A. Stähle, O. Tomé et al. · Supportive Care in Cancer · 2005 · 70 citations

Medicine, Oncology, Pharmacology +13

First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: Results of the MONICA trial

M. Kaufmann, Nicolaì Maass, Serban Dan Costa et al. · European Journal of Cancer · 2010 · 38 citations

Medicine, Oncology, Pharmacology +12

Breast Cancer Treatment with Everolimus and Exemestane for Er+ Women - Results of the 2Nd Interim Analysis of the Non-Interventional Trial Brawo

Peter A. Fasching, Thomas Decker, Christoph Uleer et al. · Annals of Oncology · 2014 · 19 citations

Medicine, Oncology, Surgery +16